Kala Pharmaceuticals Company Insiders

KALA Stock  USD 6.91  0.11  1.62%   
Kala Pharmaceuticals' insiders are aggressively selling. The analysis of insiders' sentiment of trading Kala Pharmaceuticals stock suggests that vertually all insiders are panicking at this time. Kala Pharmaceuticals employs about 43 people. The company is managed by 15 executives with a total tenure of roughly 46 years, averaging almost 3.0 years of service per executive, having 2.87 employees per reported executive.
Mark Iwicki  Chairman
Chairman of the Board and Presidentident, CEO
Michele LaRussa  President
Senior Vice President - Regulatory Affairs and Quality Assurance

Kala Pharmaceuticals' Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2024-06-26Todd BazemoreDisposed 4653 @ 4.75View
2024-05-31Todd BazemoreDisposed 2093 @ 6.09View
2024-01-04Mark T IwickiDisposed 4539 @ 6.73View
Monitoring Kala Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kala Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Kala Stock refer to our How to Trade Kala Stock guide.

Kala Pharmaceuticals' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Kala Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Kala will maintain a workforce of about 33000000 employees by December 2024.
 
Covid

Kala Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of (0.4025) % which means that it has lost $0.4025 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.4811) %, meaning that it created substantial loss on money invested by shareholders. Kala Pharmaceuticals' management efficiency ratios could be used to measure how well Kala Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to -0.79. In addition to that, Return On Capital Employed is expected to decline to -0.86. At present, Kala Pharmaceuticals' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 98.6 M, whereas Total Assets are forecasted to decline to about 53.2 M.
The current year's Common Stock Shares Outstanding is expected to grow to about 2.6 M, whereas Net Loss is forecasted to decline to (42.4 M).

Kala Pharmaceuticals Workforce Comparison

Kala Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 9,814. Kala Pharmaceuticals adds roughly 43.0 in number of employees claiming only tiny portion of equities under Health Care industry.

Kala Pharmaceuticals Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kala Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kala Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Kala Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-06-01
1.2
12
10
 28,400 
 48,135 
2024-03-01
2.0
12
6
 225,700 
 11,400 
2023-06-01
0.8727
48
55
 1,111,237 
 118,545 
2023-03-01
2.0
16
8
 174,956 
 526.00 
2022-12-01
0.2
1
5
 1,600 
 1,424 
2022-06-01
1.0
11
11
 460,000 
 6,110,123 
2022-03-01
0.8333
5
6
 1,557,000 
 22,185 
2021-12-01
1.0
7
7
 5,820,777 
 102,297 
2021-06-01
1.1429
8
7
 1,812,709 
 26,435 
2021-03-01
7.0
14
2
 1,050,499 
 56,500 
2020-06-01
3.5
21
6
 403,711 
 113,269 
2020-03-01
12.0
12
1
 16,216,411 
 31,000 
2019-09-01
1.0
2
2
 4,824 
 4,824 
2018-03-01
11.5
23
2
 1,504,298 
 9,769 
2017-09-01
0.6066
37
61
 17,906,039 
 84,234,264 

Kala Pharmaceuticals Notable Stakeholders

A Kala Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Kala Pharmaceuticals often face trade-offs trying to please all of them. Kala Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Kala Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Mark IwickiChairman of the Board and Presidentident, CEOProfile
Michele LaRussaSenior Vice President - Regulatory Affairs and Quality AssuranceProfile
Todd BazemorePresident COOProfile
Vincent KosewskiSenior Vice President - Manufacturing and Supply Chain ManagementProfile
Mary CPACFO TreasurerProfile
CPA CPACFO TreasurerProfile
Jill SteierExecutive CommunicationsProfile
Carl RennieExecutive ManagementProfile
MBA JDChief OfficerProfile
Kim BrazzellChief Medical OfficerProfile
Justin HanesFounder BoardProfile
Josiah CraverSenior ControllerProfile
Eric TrachtenbergGeneral Counsel, Corporate SecretaryProfile
Francis MDChief AdvisorProfile
James PatnoeCommercial AccessProfile

About Kala Pharmaceuticals Management Performance

The success or failure of an entity such as Kala Pharmaceuticals often depends on how effective the management is. Kala Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Kala management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Kala management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.75)(0.79)
Return On Capital Employed(0.82)(0.86)
Return On Assets(0.75)(0.79)
Return On Equity(5.62)(5.34)
Please note, the presentation of Kala Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kala Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Kala Pharmaceuticals' management manipulating its earnings.

Kala Pharmaceuticals Workforce Analysis

Traditionally, organizations such as Kala Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Kala Pharmaceuticals within its industry.

Kala Pharmaceuticals Manpower Efficiency

Return on Kala Pharmaceuticals Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee981.4K
Net Loss Per Executive2.8M
Working Capital Per Employee1M
Working Capital Per Executive3M

Complementary Tools for Kala Stock analysis

When running Kala Pharmaceuticals' price analysis, check to measure Kala Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kala Pharmaceuticals is operating at the current time. Most of Kala Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kala Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kala Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kala Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm